ALSO NOTED: Abbott stent gets review; Studies ease finasteride fears; The Pill cuts cancer risk;

> And in other stent news, the FDA plans to schedule an advisory committee meeting to discuss Abbott Laboratories' Xience drug-coated version, already sold overseas. Report

> New studies may ease fears of finasteride, a generic drug that's effective in preventing prostate cancer--but until now was thought to promote fast-growing tumors in those patients who did develop cancer. Release

> The Pill may actually cut cancer risk--up to 12 percent, in fact--provided women don't take it for longer than eight years, according to a new study published in the British Medical Journal. Report

> Natco Pharma has launched a generic version of Lenalid, used to treat Myelo Dysplastic Syndrome. Report

> Venture capitalists are betting big on nanotechnology. Report

And Finally... Pharma companies may be experts at some technologies, but their online advertising is mired in the Internet dark ages. Report